The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

By P. Hegde, V. Karanikas, S. Evers. Clinical Cancer Research, 2016

788 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/f58a896abc18417223d7fe9bde3a778ecbd6acab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Quynh-Thu Le

In Oncology

1. R. Ferris

Citations in the corpus

• Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors (2018, methodology): “Simultaneously, in another model based on the status of TIL, tumor immune microenvironment is classified into three subtypes: immune inflamed subtype, excluded infiltrate subtype, and immune ignorance subtype [48].”
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) (2019, background): “Similarly, overcoming challenges such as tumor immune resistance, immune escape and immune-related adverse events will be critical to advancing the field [168].”